Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Cancer Immunol Res. 2014 Aug 12;2(10):949–961. doi: 10.1158/2326-6066.CIR-14-0058

Table 2. Summary of Treatment-Related Adverse Events.

Adverse Event All Grades Grade 3 or 4
# Patients % # Patients %
Local vaccine site reactions
 Erythema/induration 20 100 0 0
 Pruritus 20 100 0 0
 Pain/soreness/tenderness 17 85 0 0
 Local rash at/near vaccine site 7 35 1 5
 Blister formation 5 25 0 0
 Hyperpigmentation 4 20 0 0
 Ecchymosis (bruising) 3 15 0 0
 Local edema 2 10 0 0
 Vaccine site flare 2 10 0 0
 Groin tightness 1 5 0 0
Systemic toxicities
 Fatigue 8 40
 Urticaria 7 35 2 10
 Pruritus (distant from vaccine site) 6 30 1 5
 Fever 5 25
 Flu-like symptoms/myalgia 4 20
 Lymphadenopathy 4 20
 Abdominal pain 3 15 1 5
 Rash (distant from vaccine site) 3 15 1 5
 Achiness/malaise 3 15
 Chills 3 15
 Dizziness 2 10
 Anorexia 1 5
 Erythema (distant from vaccine site) 1 5
 Headache 1 5
 Nausea 1 5
 Arm pain 1 5
 Cancer site pain 1 5
 Leg tenderness 1 5

NOTE: Data are given as any incident per patient, for a maximum of 20 counts per event.